Policy Analysis Inc, PAI, 4 Davis Court, Brookline, MA, 02445, USA.
BMC Cancer. 2012 Aug 22;12:362. doi: 10.1186/1471-2407-12-362.
Economic implications of chemotherapy-induced febrile neutropenia (FN) in European and Australian clinical practice are largely unknown.
Data were obtained from a European (97%) and Australian (3%) observational study of patients with non-Hodgkin's lymphoma (NHL) receiving CHOP (±rituximab) chemotherapy. For each patient, each cycle of chemotherapy within the course, and each occurrence of FN within cycles, was identified. Patients developing FN in a given cycle ("FN patients"), starting with the first, were matched to those who did not develop FN in that cycle ("comparison patients"), irrespective of subsequent FN events. FN-related healthcare costs (£2010) were tallied for the initial FN event as well as follow-on care and FN events in subsequent cycles.
Mean total cost was £5776 (95%CI £4928-£6713) higher for FN patients (n = 295) versus comparison patients, comprising £4051 (£3633-£4485) for the initial event and a difference of £1725 (£978-£2498) in subsequent cycles. Among FN patients requiring inpatient care (76% of all FN patients), mean total cost was higher by £7259 (£6327-£8205), comprising £5281 (£4810-£5774) for the initial hospitalization and a difference of £1978 (£1262-£2801) in subsequent cycles.
Cost of chemotherapy-induced FN among NHL patients in European and Australian clinical practice is substantial; a sizable percentage is attributable to follow-on care and subsequent FN events.
在欧洲和澳大利亚的临床实践中，化疗引起的发热性中性粒细胞减少症（FN）的经济影响在很大程度上是未知的。
数据来自一项针对接受 CHOP（±利妥昔单抗）化疗的非霍奇金淋巴瘤（NHL）患者的欧洲（97%）和澳大利亚（3%）观察性研究。对于每个患者，在治疗过程中的每个周期以及每个周期中的 FN 发作中，都确定了每个周期的化疗。在给定周期中发生 FN 的患者（“FN 患者”），从第一周期开始，与未在该周期中发生 FN 的患者（“对照患者”）相匹配，而与随后的 FN 事件无关。对首次 FN 事件以及后续治疗和随后周期中的 FN 事件，汇总了与 FN 相关的医疗保健费用（£2010）。
与对照患者相比，FN 患者（n=295）的总费用平均高出£5776（95%CI £4928-£6713），其中包括首次事件的£4051（£3633-£4485）和随后周期中差异£1725（£978-£2498）。在需要住院治疗的 FN 患者中（所有 FN 患者的 76%），总费用平均高出£7259（£6327-£8205），其中包括首次住院的£5281（£4810-£5774）和随后周期中差异£1978（£1262-£2801）。
在欧洲和澳大利亚的临床实践中，NHL 患者化疗引起的 FN 的成本很高；很大一部分归因于后续治疗和随后的 FN 事件。
